Trulieve Cannabis Q4 Adjusted EPS $(0.12) Beats $(0.16) Estimate, Sales $287.00M Beat $267.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
Trulieve Cannabis (TCNNF) reported Q4 adjusted EPS of $(0.12), surpassing the $(0.16) estimate, with sales of $287.00M exceeding the $267.95M forecast. This represents a 33.33% improvement in losses per share and a 7.11% sales beat year-over-year, despite a 3.85% decrease in sales from the same period last year.
February 29, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Trulieve Cannabis reported a significant beat on both EPS and sales estimates for Q4, showing improvement in losses and exceeding sales forecasts.
Beating both EPS and sales estimates typically generates positive investor sentiment, potentially leading to a short-term increase in stock price. The improvement in losses and sales performance, despite a slight year-over-year sales decrease, indicates operational efficiency and market strength, which are positive signals for investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100